Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: Procedural and long-term results

Circulation

Volumn 108, Issue 11, 2003, Pages 1310-1315

  Kereiakes, Dean J ^a,m   Szyniszewski, Arthur M ^b   Wahr, Dennis ^b   Herrmann, Howard C ^c   Simon, Daniel I ^d   Rogers, Campbell ^f,g   Kramer, Paul ^h   Shear, Wendy ⁱ   Yeung, Alan C ^j   Shunk, Kendrick A ^k   Chou, Tony M ^k   Popma, Jeffrey ^e   Fitzgerald, Peter ^j   Carroll, Tanya E ^l   Forer, David ^l   Adelman, Daniel C ^l  

^a Ohio Heart and Vascular Center   (United States)

^b Michigan Heart and Vascular Institute   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d Interventional Cardiology Section   (United States)

^e Cardiovascular Disease   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^h SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l PHARMACYCLICS INC   (United States)

^m The Carl & Edyth Lindner Center for Research & Education   (United States)

more..

Author keywords

Atherosclerosis; Motexafin lutetium; Phototherapy; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPHENHYDRAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; HYDROCORTISONE; LUTETIUM TEXAPHYRIN; METALLOPORPHYRIN; PHOTOSENSITIZING AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BALLOON DILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ILLUMINATION; IMAGE ANALYSIS; INTRAVASCULAR ULTRASOUND; LASER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHOTOACTIVATION; PHOTOTHERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; Q WAVE; QUANTITATIVE ANALYSIS; RASH; RED LIGHT; RESTENOSIS; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHOTOCHEMOTHERAPY; RADIATION RESPONSE; RADIOGRAPHY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METALLOPORPHYRINS; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; STENTS; TREATMENT OUTCOME;

EID: 0141431006     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000087602.91755.19     Document Type: Article

References (29)

1. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
2. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
3. Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg. 1996;14:343-348.
4. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol. 2000;59:733-739.
5. Mody T, Fu L, Sessler JL. Texaphyrins: synthesis and development of a novel class of therapeutic agents. Prog Inorg Chem. 2001;49:551-598.
6. Kessel D, Sykes E. Porphyrin accumulation by atheromatous plaques of the aorta. Photochem Photobiol. 1984;40:59-61.
7. Hsiang YN, Crespo MT, Richter AM, et al. In vitro and in vivo uptake of benzoporphyrin derivative into human and miniswine atherosclerotic plaque. Photochem Photobiol. 1993;57:670-674.
8. Kessel D, Luo Y, Deng Y, et al. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol. 1997;65:422-426.
9. Straight R, Vincent G, Hammond E, et al. Porphyrin retention and photodynamic treatment of diet induced atherosclerotic lesions in pigs. In: Jori G, Perria C, eds. Photodynamic Therapy of Tumors and Other Diseases. Padova, Italy: Libreria Progetto; 1986:350-352.
10. Woodburn KW, Young S, Fan Q, et al. Selective uptake of texaphyrins by atheromatous plaque. SPIE Proc. 1996;2671:62-71.
11. Chen Z, Woodburn KW, Shi C, et al. Photodynamic therapy with Motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol. 2001;21:759-764.
12. Hayase M, Woodburn KW, Perlroth J, et al. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc Res. 2001;49:449-455.
13. Henderson B, Dougherty T. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
14. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905.
15. Rockson SG, Lorenz DP, Cheong WF, et al. Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy. Circulation. 2000;102:591-596.
16. Chou TM, Woodburn K, Cheong WF, et al. Photodynamic therapy: applications in atherosclerotic vascular disease with Motexafin lutetium. Cathet Cardiovasc Intervent. 2002;57:387-394.
17. Mackie RW, Vincent GM, Fox J, et al. In-vivo canine coronary artery laser irradiation: photodynamic therapy using dihematoporphyrin ether and 632 nm laser. Lasers Surg Med. 1991;11:535-544.
18. Vincent GM, Fox J, Charlton G, et al. Presence of blood significantly decreases transmission of 630 mm laser light. Lasers Surg Med. 1991;11:399-403.
19. Young SW, Woodburn KW, Wright M, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol. 1996;63:892-897.
20. Wilson B. Light sources for photodynamic therapy. Photodynamic News. 1998;1:6-8.
21. Rockson SG, Kramer P, Razavi M, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 2000;102:2322-2324.
22. Kastrafi A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816.
23. Pacho J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-1288.
24. Morice MC, Serruys PW, Sousa JE, et al for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
25. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
26. Cusack MR, Marber MS, Lambiase PD, et al. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol. 2002;39:1917-1923.
27. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12.
28. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-808.
29. Seshiah PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation. 2002;105:174-180.